CIK 1439589
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2021-Q2. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Health Care Equipment & Supplies | 71.28% | 1 |
| Pharmaceuticals & Biotechnology | 26.03% | 4 |
| Unclassified | 2.69% | 1 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | LYRA | Lyra Therapeutics, Inc. | Health Care | 71.28% |
| 2 | XFOR | X4 Pharmaceuticals, Inc | Health Care | 11.70% |
| 3 | ATYR | aTYR PHARMA INC | Health Care | 8.42% |
| 4 | DARE | Dare Bioscience, Inc. | Health Care | 3.87% |
| 5 | GNCAQ | GENOCEA BIOSCIENCES INC | Unclassified | 2.69% |
| 6 | PULM | Pulmatrix, Inc. | Health Care | 2.04% |
5/6 names classified · sector 97.3% of weight · industry 97.3% · mkt cap 97.3%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 97.3% of the book is sector-classified (unclassified names shown, never dropped).
Only 0% of book weight classified — the grid is NOT representative of the whole book.
Classified: 0.0% of book weight (0/6 names) · unclassified 100.0%: LYRA, XFOR, ATYR, DARE, GNCAQ, PULM. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | LYRALYRA THERAPEUTICS INC | 1,100,852 | $10M | 71.3% | HOLD |
| 2 | XFORX4 Pharmaceuticals, Inc. | 311,492 | $2M | 11.7% | HOLD |
| 3 | ATYRATYR PHARMA INC | 130,572 | $1M | 8.4% | HOLD |
| 4 | DAREDARE BIOSCIENCE INC | 326,240 | $545,000 | 3.9% | HOLD |
| 5 | GNCAQGENOCEA BIOSCIENCES INC | 197,345 | $379,000 | 2.7% | HOLD |
| 6 | PULMPULMATRIX INC COM | 359,441 | $288,000 | 2.0% | HOLD |
Where this firm's principals came from and which firms its alumni went on to found.
